| Exviera (dasabuvir) / AbbVie |
|
 | PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | EASL 2014: SAPPHIRE-I | | Apr 2014 - Apr 2014: EASL 2014: SAPPHIRE-I | | SAPPHIRE-I | | Apr 2014 - Apr 2014: SAPPHIRE-I | | DDW 2014: SAPPHIRE-I | | Apr 2014 - Apr 2014: DDW 2014: SAPPHIRE-I | | SAPPHIRE-I | | Nov 2013 - Nov 2013: SAPPHIRE-I | | More | |
|
|
| Completed | 3 | 636 | NA | ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ABT-450/r/ABT-267, Placebo for ABT-333, Placebo for ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection | 10/13 | 10/14 | | |
|
|
|
|
|
|
| PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | SAPPHIRE-II | | Apr 2014 - Apr 2014: SAPPHIRE-II | | DDW 2014: SAPPHIRE-II | | Apr 2014 - Apr 2014: DDW 2014: SAPPHIRE-II | | EASL 2014: SAPPHIRE II | | Mar 2014 - Mar 2014: EASL 2014: SAPPHIRE II | | SAPPHIRE-II trial | | Dec 2013 - Dec 2013: SAPPHIRE-II trial | | More | |
|
|
| Completed | 3 | 395 | NA | ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ABT-450/r/ABT-267, Placebo for ABT-333, Placebo for ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection | 11/13 | 10/14 | | |
|
|
|
|
|
|
| PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | ACG 2014 - PEARL-II and PEARL-III | | Sep 2014 - Sep 2014: ACG 2014 - PEARL-II and PEARL-III | | ICAAC 2014 - PEARL-II and PEARL-III | | Sep 2014 - Sep 2014: ICAAC 2014 - PEARL-II and PEARL-III | | PEARL III & PEARL IV | | May 2014 - May 2014: PEARL III & PEARL IV | | EASL 2014: PEARL-III | | Apr 2014 - Apr 2014: EASL 2014: PEARL-III | | CROI 2014: PEARL III | | Mar 2014 - Mar 2014: CROI 2014: PEARL III | | PEARL III | | Jan 2014 - Jan 2014: PEARL III | | More | |
|
|
| Completed | 3 | 419 | NA | ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection | 12/13 | 08/14 | | |
|
|
|
|
|
|
|
|
| PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | AASLD 2014: PEARL IV | | Oct 2014 - Oct 2014: AASLD 2014: PEARL IV | | PEARL III & PEARL IV | | May 2014 - May 2014: PEARL III & PEARL IV | | DDW 2014: PEARL-IV | | Apr 2014 - Apr 2014: DDW 2014: PEARL-IV | | PEARL-IV | | Jan 2014 - Jan 2014: PEARL-IV | | More | |
|
|
| Completed | 3 | 305 | NA | ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for Ribavirin | AbbVie | Chronic Hepatitis C Infection | 12/13 | 09/14 | | |
|
|
|
|
|
PEARL-II, NCT01674725 / 2011-005740-95: A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C |
| PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II | | ACG 2014 - PEARL-II and PEARL-III | | Sep 2014 - Sep 2014: ACG 2014 - PEARL-II and PEARL-III | | ICAAC 2014 - PEARL-II and PEARL-III | | Sep 2014 - Sep 2014: ICAAC 2014 - PEARL-II and PEARL-III | | PEARl-II | | May 2014 - May 2014: PEARl-II | | DDW 2014: PEARl-II | | Apr 2014 - Apr 2014: DDW 2014: PEARl-II | | PEARL-II | | Jan 2014 - Jan 2014: PEARL-II | | More | |
|
|
| Completed | 3 | 187 | NA | ABT-450/r/ABT-267, ABT-333, ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection | 01/14 | 10/14 | | |
|
|
|
|
|
|
TURQUOISE-II, NCT01704755 / 2012-003088-23: A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis |
|
|
| Completed | 3 | 381 | NA | ABT-450/r/ABT-267, ABT-333, Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir, Ribavirin (RBV) | AbbVie (prior sponsor, Abbott) | Chronic Hepatitis C Infection, Compensated Cirrhosis | 01/14 | 09/14 | | |
|
|
|
|
|
|
|
MALACHITE 1, NCT01854697 / 2012-003754-84: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before |
|
|
| Completed | 3 | 311 | NA | ABT-450/r/ABT-267, ABT-333, Viekira Pak, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Holkira Pak, Ribavirin, Telaprevir, Pegylated Interferon alpha 2-a (PegIFN) | AbbVie | Chronic Hepatitis C Infection | 11/14 | 07/15 | | |
|
MALACHITE II, NCT01854528 / 2012-003738-18: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults |
|
|
| Completed | 3 | 148 | NA | ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Pegylated Interferon a-2a (PegINF), Telaprevir | AbbVie | Chronic Hepatitis C Infection | 11/14 | 07/15 | | |
|
TURQUOISE-III, NCT02219503 / 2014-001953-18: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis |
|
|
| Completed | 3 | 60 | NA | Ombitasvir/Paritaprevir/Ritonavir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, Ritonavir also known as norvir, Dasabuvir, ABT-333 | AbbVie | Chronic Hepatitis C Infection, Compensated Cirrhosis | 06/15 | 09/15 | | |
NCT02399345: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults |
|
|
| Completed | 3 | 10 | Canada, RoW | ombitasvir/paritaprevir/ritonavir, dasabuvir, Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333, sofosbuvir (SOF), ribavirin (RBV) | AbbVie | Chronic Hepatitis C Virus (HCV Infection Genotype 1) | 11/15 | 11/15 | | |
Turquoise-IV, NCT02216422: A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection |
|
|
| Completed | 3 | 36 | US, RoW | Ombitasvir/Paritaprevir/Ritonavir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, Ritonavir also known as norvir, Dasabuvir, ABT-333, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C Virus (HCV) Infection | 12/15 | 12/15 | | |
2014-004111-37: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C VírusInfection witb Cirrhosis |
|
|
| Completed | 3 | 1 | Europe | ABT-450/r/ABT-267+ABT-333 | BUDAI HEPATOLÓGIAI CENTRUM | | | | | |
2014-004268-38: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection |
|
|
| Completed | 3 | 1 | Europe | ABT-450/ritonavir/ABT-267, ABT-333, Film-coated tablet, | Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | | | | | |
TURQUOISE-CPB, NCT02219477 / 2014-001477-13: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis |
|
|
| Completed | 3 | 36 | US, Canada, Europe | ombitasvir/paritaprevir/ritonavir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as norvir, dasabuvir, ABT-333, ribavirin | AbbVie | Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus | 06/16 | 03/17 | | |
NCT02442271: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil |
|
|
| Completed | 3 | 222 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ribavirin | AbbVie | Chronic Hepatitis C Infection | 07/16 | 09/16 | | |
NCT02476617: Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults |
|
|
| Completed | 3 | 25 | NA | ombitasvir/paritaprevir/ritonavir, ABT-267/ABT-450/ritonavir, dasabuvir, ABT-333, ribavirin | AbbVie | Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a | 08/16 | 12/16 | | |
NCT02442284: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection |
|
|
| Completed | 3 | 99 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, Ribavirin | AbbVie | Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus | 08/16 | 10/16 | | |
| Completed | 3 | 166 | NA | ombitasvir/paritaprevir/ritonavir, ABT-267/ABT-450/r, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir, ABT-333 | AbbVie | Hepatitis C Infection, Hepatitis C Virus | 08/16 | 12/16 | | |
GEODE - I, NCT02504099 / 2015-001049-10: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma |
|
|
| Terminated | 3 | 3 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, Technivie, ribavirin | AbbVie | Chronic Hepatitis C Infection | 09/16 | 12/16 | | |
NCT02517528: ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis |
|
|
| Completed | 3 | 104 | NA | ABT-450/r/ABT-267, ombitasvir/paritaprevir/ritonavir, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, ABT-333, dasabuvir, ribavirin | AbbVie | Chronic Hepatitis C Virus (HCV) | 09/16 | 03/17 | | |
NCT01773070 / 2012-003073-26: A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study |
|
|
| Completed | 3 | 478 | NA | ABT-450/ritonavir, ABT-450 also known as paritaprevir, ABT-333, dasabuvir, ABT-267, ombitasvir | AbbVie (prior sponsor, Abbott) | Hepatitis C | 10/16 | 10/16 | | |
NCT02517515: ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 650 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir | AbbVie | Hepatitis C Virus (HCV) | 10/16 | 06/17 | | |
GEODE II, NCT02609659: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection |
|
|
| Completed | 3 | 105 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ribavirin | AbbVie | Hepatitis C Virus (HCV) | 10/16 | 12/16 | | |
NCT02487199 / 2015-002012-33: Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease |
|
|
| Completed | 3 | 18 | NA | ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, Technivie, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267 | AbbVie | Hepatitis C Virus (HCV) | 12/16 | 12/16 | | |
NCT02207088: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease |
|
|
| Completed | 3 | 68 | NA | ombitasvir/paritaprevir/ritonavir, ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, dasabuvir, ABT-333, Ribavirin, RBV | AbbVie | Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis, Severe Renal Impairment, End-stage Renal Disease | 12/16 | 12/16 | | |
NCT02646111: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures |
|
|
| Unknown status | 3 | 120 | NA | 12 weeks without Ribavirin, Triple therapy, 12 weeks with Ribavirin, 24 weeks with Ribavirin | Tel-Aviv Sourasky Medical Center | Hepatitis C | 01/18 | 01/19 | | |
| Completed | 3 | 83 | Europe, RoW | Paritaprevir/ritonavir/ombitasvir, Viekira Pak, Dasabuvir, Ribavirin, Glecaprevir/pibrentasvir | Kirby Institute, AbbVie | Hepatitis C, Acute | 04/21 | 04/21 | | |
TOPAZ II, NCT02167945: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 615 | US | ABT-450/r/ABT-267, ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, Paritaprevir/ritonavir/ombitasvir also known as Viekirax, ABT-333, ABT-333 also known as dasabuvir, ABT-333 also known as Exviera, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | 05/21 | 05/21 | | |
TOPAZ-I, NCT02219490 / 2014-001022-14: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 1596 | Europe, Canada, RoW | ABT-450/r/ABT-267, ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, Paritaprevir/ritonavir/ombitasvir also known as Viekirax, ABT-333, ABT-333 also known as dasabuvir, ABT-333 also known as Exviera, Ribavirin (RBV) | AbbVie | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | 05/21 | 05/21 | | |
2014-002962-57: Hepatitis C meggyógyítása, cryoglobunaemia és szövödményeinek (vaculitis, neuritis) megszüntetése |
|
|
| Completed | 3 | 1 | Europe | ABT-450/r/ABT-267; ABT333 | Egyesített Szent István és Szent László Kórház - Rendelőintézet | | | | | |
TURQUOISE-I, NCT01939197 / 2012-005143-24: A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection |
|
|
| Completed | 2/3 | 318 | NA | ABT-450/r/ABT-267, ombitasvir/paritaprevir/ritonavir, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, ABT-333, Dasabuvir, ribavirin | AbbVie | Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics | 07/16 | 10/16 | | |
|
|
|
|
| Completed | 2/3 | 64 | Europe, US | Ombitasvir/paritaprevir/ritonavir, Ombitasvir also known as ABT-267, Paritaprevir also known as ABT-450, Ombitsvir/paritaprevir/ritonavir also known as Viekirax, Dasabuvir, Exviera, ABT-333, Ribavirin, Ombitasvir mini tablet, ABT-267, Paritaprevir mini tablet, ABT-450, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution | AbbVie | Chronic Hepatitis C Infection | 11/20 | 11/20 | | |
| Completed | 2/3 | 23 | RoW | Ledipasvir/Sofosbuvir, Harvoni®, GS-7977, GS-5885, Sofosbuvir and Daclatasvir, Sovaldi®, GS-7977, Daklinza®,BMS-790052, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, VIEKIRA PAK™, Entecavir, BARACLUDE®, Tenofovir disoproxil, VIREAD® | Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University | Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation | 05/21 | 08/21 | | |
